Delhi The Buzz

Decision on allowing tractor rally only after completing modalities: Delhi Police

Tribune News Service

New Delhi, Jan 23

The Delhi Police have said that the talks with the protesting farmers over granting them permission to hold their proposed tractor rally inside the territory of the national capital on January 26 are “at the final stages”, as several of the modalities need to be fixed in “black & white”.

A senior police official said, a final decision on granting permission could be taken only after everything including the route, number of vehicles, their owners’ identification, and vehicles’ registration numbers are shared with the authorities, as the issue is “quite sensitive”.

READ: Farmers agree to hold Republic Day rally on Delhi’s inner roads

“All these information have been sought from the farmers and once they are shared, the same will be analysed and accordingly a final decision will be arrived at,” said the official.

Meanwhile, the police have issued an advisory saying that people would be allowed to watch the Republic Day parade at Rajpath “strictly on the production of an invitation card or a ticket”. They also said that those below 15 years of age will not be allowed at the event.

“This year, Entry to RDC-2021 will be strictly through Invitation Card/Ticket only! All those, who don’t have a valid Invitation Card/Ticket are advised to watch the live program at home. Children below 15 years of age are not allowed to RDC-2021 at Rajpath,” the Delhi Police said in a tweet, adding that there would be “no free entry to the programme this year”.

The national capital has been brought under an unprecedented ground-to-air security cover, with thousands of armed personnel keeping a tight vigil in view of the Republic day celebrations. Patrolling has been intensified in the busy market areas of the city.

Security arrangements have also been tightened at the border areas in view of a proposed tractor parade by the farmers agitating against the Centre’s new farm laws on January 26.

Source link

Coronavirus COVID-19 Delhi The Buzz

Govt exploring modalities of emergency authorisation of COVID-19 vaccine

New Delhi, November 22

The government is exploring the modalities of emergency authorisation and usage of anti-coronavirus vaccines pending completion of phase-three clinical trial and regular licensure.

The issue of advance purchase commitment for vaccines, including pricing, was also discussed in a recent meeting attended by NITI Aayog Member (Health) Vinod Paul, Principal Scientific Adviser to the government K Vijay Raghavan and Union Health Secretary Rajesh Bhushan.

“It was decided that the PMO-constituted Vaccine Task Force (VTF) will lay down the principles for emergency use authorisation while the National Expert Group On Vaccine Administration for COVID-19 (NEGVAC) should take the lead in setting the principles for advance market commitment, including vaccine pricing,” a source said.

These developments assume significance against the backdrop of Pfizer seeking emergency use authorisation of its COVID-19 vaccine from the US regulators. Another US-based biotechnology giant, Moderna, said it also intends to apply for an emergency use authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks.

Meanwhile, five vaccines are under different phases of clinical trials in India. The Serum Institute of India is conducting the phase-three trial of the Oxford-AstraZeneca COVID-19 vaccine, while Bharat Biotech and ICMR has already started the phase-three trial of the indigenously developed COVAXIN jab.

An indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country. Dr Reddy’s Laboratories will soon start combined phase two and three trials of the Russian COVID-19 vaccine Sputnik V in India.

According to the source, an urgent meeting of the vaccine task force (VTF) with experts will be convened to review the scientific status of vaccines globally and whether, if so how and when should the decision on emergency authorisation of vaccines be taken.

The terms of references for two major bodies dealing with vaccine introduction—the National Technical Advisory Group on Immunisation (NTAGI) and the Central Drug Standards and Control Organisation (CDSCO) — will be set and their roles clearly defined for authorisation and emergency authorisation.

It was also agreed at the meeting that one point of contact will be responsible for examining and responding to authorisations given (or in the pipeline), globally, the source said.

Towards advance market commitment, NEGVAC should lay down principles for procurement and price negotiations. Using these principles, negotiations should be speedily initiated.

It was also decided at the meeting that a NEGVAC group should be proactively reaching out to each company as their results from phase three are announced, a source said.

Pfizer and its German partner BioNTech have announced that its vaccine appears 95 per cent effective at preventing mild to severe COVID-19 disease in a large, ongoing study. Moderna has also announced that its COVID-19 vaccine has shown to be 94.5 per cent effective in preventing the deadly disease. — PTI


Source link